超罕见疾病药物开发模式:传统盈利模式难以为继,替代路径探索
Drug development models for ultra-rare disorders
传统营利模式难以支撑罕见及超罕见神经系统疾病的药物研发,需探索替代方案。文章讨论了多个可行项目与倡议,包括AAV基因治疗平台项目、FDA基于合理机制的罕见病指导原则应用,以及慈善资助与协作网络等新型研发路径。
- Comment
- Published: 16 November 2026
Nature Reviews Neurology (2026) Cite this article
The traditional for-profit model of drug development is not sustainable for rare and ultra-rare neurological conditions, so alternative models are needed. Here, we consider some of the programmes and initiatives that are providing viable pathways.
This is a preview of subscription content, access via your institution
Access options
Access through your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
32.70 € / 30 days cancel any time
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
39,95 €
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
References
Yates, N. & Hinkel, J. The economics of moonshots: value in rare disease drug development. Clin. Transl. Sci. 15, 809–812 https://doi.org/10.1111/cts.13270 (2022).
Brooks, P. J. et al. The Bespoke Gene Therapy Consortium: facilitating development of AAV gene therapies for rare diseases. Nat. Rev. Drug Discov. 23, 157–158 https://doi.org/10.1038/d41573-024-00020-8 (2024).
Brooks, P. J. et al. The Platform Vector Gene Therapies Project: increasing the efficiency of adeno-associated virus gene therapy clinical trial startup. Hum. Gene Ther. 31, 1034–1042 https://doi.org/10.1089/hum.2020.259 (2020).
Hendry, C. & Zhou, J. & Jiang, Y.-h. Applying the FDA’s plausible mechanism guidance across the rare disease landscape. Nat. Genet. https://doi.org/10.1038/s41588-026-02750-4 (2026).
Karin, I., Büchner, B., Gauzy, F., Klucken, A. & Klopstock, T. Treat Iron-Related Childhood-Onset Neurodegeneration (TIRCON)—an international network on care and research for patients with neurodegeneration with brain iron accumulation (NBIA). Front. Neurol. 12, 642228 https://doi.org/10.3389/fneur.2021.642228 (2021).
Austin, C. P. et al. Future of rare diseases research 2017–2027: an IRDiRC perspective. Clin. Transl. Sci. 11, 21–27 https://doi.org/10.1111/cts.12500 (2018).
Hayflick, S. J. CoA-Z in pantothenate kinase-associated neurodegeneration (PKAN). ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04182763 (2025).
A within-subject dose escalation study of a vitamin supplement for PKAN - PKAN-II. World Health Organization https://trialsearch.who.int/Trial2.aspx?TrialID=NL-OMON55013 (2024).
Majerol, M., Chaudhury, A., Traugott, C. & Mitta, V. The cell and gene therapy access model. JAMA 334, 1615–1616 https://doi.org/10.1001/jama.2025.16537 (2025).
Our venture philanthropy model. Cystic Fibrosis Foundation https://www.cff.org/about-us/our-venture-philanthropy-model (2024).
Author information
Authors and Affiliations
Department of Molecular & Medical Genetics, Oregon Health & Science University, Portland, OR, USA
Susan J. Hayflick
Raiden Science Foundation, Beaverton, OR, USA
Chris Andon
Department of Epidemiology, University Medical Center Groningen, Groningen, Netherlands
Antoinette D. I. van Asselt
Innovation Center, University Medical Center Groningen, Groningen, Netherlands
Harm Jan Hektor
Department of Biomedical Sciences, European Research Institute for the Biology of Ageing, University Medical Center Groningen, Groningen, Netherlands
Ody Sibon
Authors
- Susan J. Hayflick
- Chris Andon
- Antoinette D. I. van Asselt
- Harm Jan Hektor
- Ody Sibon
Corresponding author
Correspondence to Susan J. Hayflick.
Ethics declarations
Competing interests
S.J.H. is an unpaid member of the Spoonbill Foundation and Stichting Lepelaar. C.A. is an unpaid member of the Raiden Science Foundation. O.S. is an unpaid member of the Spoonbill Foundation and Stichting Lepelaar. H.J.H. is an unpaid member of the Spoonbill Foundation and Stichting Lepelaar.
About this article
Cite this article
Hayflick, S.J., Andon, C., van Asselt, A.D.I. et al. Drug development models for ultra-rare disorders. Nat Rev Neurol (2026). https://doi.org/10.1038/s41582-026-01295-8
Published: 16 November 2026
Version of record: 16 November 2026
DOI: https://doi.org/10.1038/s41582-026-01295-8
来源:Nature 健康护理主题 · nature.com